SS Innovations International, Inc. (NASDAQ: SSII) announced that its SSi Mantra surgical robotic system will be featured at the 2026 Society of Robotic Surgery Annual Meeting, scheduled for July 23-26 in Hollywood, Florida. The system will be displayed throughout the event, highlighted in multiple breakout sessions and used in a live broadcast of a remote partial nephrectomy performed by Dr. Amitabh Singh from the company’s headquarters in Gurugram, India, on a patient at Rajeev Gandhi Cancer Institute and Research Centre in New Delhi.
The demonstration underscores the potential of telesurgery to expand access to specialized care, particularly in regions with limited surgical expertise. Chairman and CEO Dr. Sudhir Srivastava will participate as a speaker and panelist in multiple sessions covering telesurgery, robotic surgery adoption, regulatory frameworks and global access to robotic care. His involvement signals the company's commitment to shaping the conversation around these critical topics.
As of July 6, 2026, the SSi Mantra system had been used in 12,375 procedures spanning more than 170 procedure types, including 653 cardiac procedures, 178 telesurgeries and 225 pediatric surgeries. Approximately 2,100 physicians have been trained on the platform. These numbers reflect the system's growing adoption and versatility across surgical disciplines.
The Society of Robotic Surgery Annual Meeting serves as a key forum for surgeons, researchers and industry leaders to discuss advancements in robotic surgery. SS Innovations' participation highlights its focus on making robotic surgery affordable and accessible globally. The company, headquartered in India but incorporated in the U.S., aims to expand the global presence of its technologically advanced, user-friendly and cost-effective solutions. For more details, the full press release is available at https://ibn.fm/YYYKE.
The implications of this announcement are significant for the healthcare industry and patients worldwide. Telesurgery, demonstrated through the live remote nephrectomy, could reduce geographic barriers to specialized surgical care, potentially improving outcomes in underserved areas. The SSi Mantra's track record—over 12,000 procedures and 2,100 trained physicians—suggests it is gaining traction as a viable alternative to established robotic systems. If adoption continues, it could drive down costs and increase competition in the robotic surgery market, benefiting hospitals and patients.
Moreover, Dr. Srivastava's participation in sessions on regulatory frameworks and global access indicates that SS Innovations is engaging with policymakers to address challenges in deploying robotic surgery worldwide. This could accelerate the development of standards for telesurgery and robotic procedures, influencing how such technologies are regulated and reimbursed. For investors, the company's presence at a major industry event and its growing procedural volume may signal strong market potential.
For ongoing updates, the latest news on SSII is available in the company’s newsroom at https://ibn.fm/SSII.
